ALR Technologies Inc. (OTCBB: ALRT) took a big step in the direction of commercializing their Health-e-Connect Diabetes Management Program with news this week that the company has partnered with the Mid-America Coalition on Health Care, or MACHC.  The new pact means that MACHC will be introducing the ALRT program for pilot participation by its membership, which consists of 67 organizations representing more than 500,000 employees in the greater Kansas City area.

Cumulatively, the Health-e-Connect Program is a robust and comprehensive remote diabetes management platform featuring ALRT’s FDA-cleared and HIPAA-compliant Health-e-Connect system, Diabetes Care Facilitators, software and hardware that is compatible with all of the major glucose meters.  It’s a complete monitoring solution to help clinicians, patients and caregivers to efficiently manage diabetes outcomes.  For care plans, the system assists in meeting HEDIS (Healthcare Effectiveness Data and Information Set) goals.

According to NCQA, HEDIS “is a tool used by more than 90 percent of America’s health plans to measure performance on important dimensions of care and service.”  Clearly, it is an important dimension to health plans and systems, such as the Health-e-Connect program, could prove invaluable in optimizing performance.

“The goal of the partnership is to assist their multi-stakeholder membership, some of which are the largest employers in the Kansas City area, better manage and reduce the costs for their employees living with diabetes,” the Richmond, Virginia-based company said in a statement on Wednesday.

MACHC President and CEO Troy Ross commented, “Throughout our 33 year history, our mission is focused on identifying and offering solutions that improve the way health care is designed and delivered so that our members can better manage their healthcare costs. The Health-e-Connect Program is an innovative tool that aligns with our mission to provide solutions that improve quality and lower the costs of expensive chronic diseases such as diabetes.”

In recent months, activity seems to be bustling at ALR Technologies.  The company has substantially strengthened its team with additions such as Certified Diabetes Educator Dr. Kent Stoneking, as Director, Diabetes Care Facilitation.  Dr. Stoneking is an affiliate member of the American Diabetes Association and the American Pharmacists Association.  ALRT has also added Jerome Hickey, a former National Account Manager at Medicis Pharmaceutical Company and Director of Managed Markets Training at Pfizer, Inc. (NYSE: PFE).

William Smith has also joined ALR Technologies as Chief Commercial Officer and board member.  Smith has a distinguished history the could open many doors for the company’s initiatives, including serving for a decade as Vice President of U.S. Public Affairs and Policy at Pfizer, before moving on to Managing Director at NSI, LLC, a Washington, D.C.-based consulting firm where he advised major pharmaceutical, biotechnology and medical device companies including AstraZeneca (NYSE: AZN), Merck (NYSE: MRK) and Genzyme, before it was bought by Sanofi (NYSE: SNY) for over $20 million in 2011.

Late in the third quarter, the company also added consulting and marketing guru Ken Robulak and Dr. Alfonso Salas to its board.  Dr. Salas has deep roots in the Columbian markets, a significant area of opportunity for ALRT to broaden its sales channels.

Bottom line is the company has openly communicated its strategic plans to bring the Health-e-Connect to market and, judging by the corporate activity, that goal is drawing closer to meaningful revenue.  The company has said that it was immersed in negotiations and this new partnership with MACHC could be the first glimpse at the large-scale potential that ALRT has offer with their technology.

ALR Technologies (ALRT) Stock Quote and News:

---

Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated three thousand dollars for one month of consultation and journalism services and to manage an investor relations/awareness program by ALR Technologies. Viper has completed prior service agreements with ALRT Technologies with full disclosure listed on our disclaimer/disclosure page. Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.